Annovis Bio stock dips after pricing $21M securities offering
Annovis Bio (NYSE:ANVS) shares fell around 19% premarket on Monday after the company priced a securities offering to raise $21M. The sale comprises 5.25M shares of common stock and warrants to ...
Annovis Bio sets terms for $21 million public offering
MALVERN, Pa. - Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage pharmaceutical company with a market capitalization of $67 million specializing in the development of treatments for neurodegenerative ...